 |
Lucinactant |
|---|---|
| Trade Name | Surfaxin |
| Orphan Indication | Respiratory distress syndrome in premature infants |
| USA Market Approval | USA |
| USA Designation Date | 1995-10-18 00:00:00 |
| Sponsor | Windtree Therapeutics, Inc.;2600 Kelly Road, Suite 100;Warrington, Pennsylvania, 18976 |
